Marshall Wace
ZBIO

Marshall Wace’s Zenas BioPharma ZBIO Stock Holding History

Marshall Wace’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.21M Sell
323,442
-178,486
-36% -$3.55M 0.01% 1115
2026
Q1 		$9.81M Buy
501,928
+494,828
+6,969% +$11.1M 0.01% 985
2025
Q4 		$258K Buy
+7,100
New +$234K ﹤0.01% 2506

Other funds holding ZBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
RPSM
Royalty Pharma Sub-Manager New York $242M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Marshall Wace's ZBIO Position: Q2 2026 in Review

Marshall Wace reduced its Zenas BioPharma (ZBIO) stake by 36% in Q2 2026, selling an estimated $3.55M and leaving 323,442 shares worth $8.21M. The position accounts for 0.01% of the portfolio, ranked #1115.

Marshall Wace first reported a position in ZBIO in Q4 2025 and has held it in 3 quarters since. The position peaked at $9.81M in Q1 2026. 145 funds tracked by Wall St. Rank hold ZBIO as of Q2 2026.

  • Marshall Wace held 323,442 shares of Zenas BioPharma worth $8.21M as of Q2 2026.
  • Marshall Wace sold 178,486 Zenas BioPharma shares in Q2 2026, an estimated $3.55M.
  • Zenas BioPharma made up 0.01% of Marshall Wace's portfolio in Q2 2026, its #1115 holding.
  • Marshall Wace first reported a position in Zenas BioPharma in Q4 2025 and has held it in 3 quarters since.
  • Marshall Wace's Zenas BioPharma position peaked at $9.81M in Q1 2026.
  • 145 funds tracked by Wall St. Rank held Zenas BioPharma as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.